Evidence map›Paper›PMID 39343807›Full record

ReviewNPJ digital medicine2024

Blending space and time to talk about cancer in extended reality.

Tamsin J Robb, Yinan Liu, Braden Woodhouse, Charlotta Windahl, Daniel Hurley, Grant McArthur, Stephen B Fox, Lisa Brown, Parry Guilford, Alice Minhinnick and 15 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ digital medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tamsin J RobbMolecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0002-1326-0755
Yinan LiuSchool of Architecture and Planning, University of Auckland, Auckland, New Zealand.
Braden WoodhouseDepartment of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0001-7162-6199
Charlotta WindahlBusiness School, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0003-3161-6134
Daniel HurleyMolecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Grant McArthurUniversity of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-8908-6071
Stephen B FoxUniversity of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7648-8896
Lisa BrownUniversity of Melbourne, Melbourne, VIC, Australia.
Parry GuilfordUniversity of Otago, Dunedin, New Zealand.ORCID http://orcid.org/0000-0002-7256-9576
Alice MinhinnickDepartment of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Christopher JacksonUniversity of Otago, Dunedin, New Zealand.
Cherie BlenkironMolecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0002-0217-3808
Kate ParkerDepartment of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Kimiora HenareAuckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0001-5113-0700
Rose McCollCentre for eResearch, University of Auckland, Auckland, New Zealand.
Bianca HauxCentre for eResearch, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0009-0008-7392-8690
Nick YoungCentre for eResearch, University of Auckland, Auckland, New Zealand.ORCID http://orcid.org/0000-0002-5261-4042
Veronica BoyleSchool of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Laird CameronAuckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
Sanjeev DevaAuckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
Jane ReeveRadiology Auckland, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
Cristin G Print *Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Michael Davis *School of Architecture and Planning, University of Auckland, Auckland, New Zealand.
Uwe Rieger *School of Architecture and Planning, University of Auckland, Auckland, New Zealand.
Ben Lawrence *Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. b.lawrence@auckland.ac.nz.

Funding

Manatu Hauora | Health Research Council of New Zealand (HRC) 20/765
6 · The paper itself

Abstract

We introduce a proof-of-concept extended reality (XR) environment for discussing cancer, presenting genomic information from multiple tumour sites in the context of 3D tumour models generated from CT scans. This tool enhances multidisciplinary discussions. Clinicians and cancer researchers explored its use in oncology, sharing perspectives on XR's potential for use in molecular tumour boards, clinician-patient communication, and education. XR serves as a universal language, fostering collaborative decision-making in oncology.

Identifiers

PMID39343807
PMCPMC11439928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.